AstraZeneca Return On Equity from 2010 to 2024

AZN Stock  USD 67.20  0.84  1.27%   
AstraZeneca PLC Return On Equity yearly trend continues to be very stable with very little volatility. Return On Equity is likely to drop to 0.14. Return On Equity is a measure of the profitability of AstraZeneca PLC ADR in relation to the equity, calculated by dividing net income by shareholder's equity. View All Fundamentals
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
0.15213448
Current Value
0.14
Quarterly Volatility
0.18068122
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many indicators such as Price To Sales Ratio of 4.37, Dividend Yield of 0.0285 or PTB Ratio of 5.12. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
Check out the analysis of AstraZeneca PLC Correlation against competitors.

Latest AstraZeneca PLC's Return On Equity Growth Pattern

Below is the plot of the Return On Equity of AstraZeneca PLC ADR over the last few years. Return on Equity is the amount of AstraZeneca PLC ADR net income returned as a percentage of AstraZeneca PLC equity. Return on equity measures AstraZeneca PLC profitability by revealing how much profit AstraZeneca PLC ADR generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. AstraZeneca PLC's Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.1710 Years Trend
Slightly volatile
   Return On Equity   
       Timeline  

AstraZeneca Return On Equity Regression Statistics

Arithmetic Mean0.20
Geometric Mean0.13
Coefficient Of Variation88.30
Mean Deviation0.11
Median0.15
Standard Deviation0.18
Sample Variance0.03
Range0.7471
R-Value(0.62)
Mean Square Error0.02
R-Squared0.38
Significance0.01
Slope(0.02)
Total Sum of Squares0.46

AstraZeneca Return On Equity History

2024 0.14
2022 0.0888
2021 0.002852
2019 0.1
2018 0.17
2017 0.2
2016 0.24

About AstraZeneca PLC Financial Statements

AstraZeneca PLC investors utilize fundamental indicators, such as Return On Equity, to predict how AstraZeneca Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Return On Equity 0.15  0.14 

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

  0.88VALN Valneva SE ADRPairCorr
  0.73FDMT 4D Molecular TherapeuticsPairCorr
  0.88JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.92LLY Eli Lilly Sell-off TrendPairCorr

Moving against AstraZeneca Stock

  0.88GILD Gilead SciencesPairCorr
  0.87BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.82NAMS NewAmsterdam PharmaPairCorr
  0.61LPCN LipocinePairCorr
  0.56PHVS Pharvaris BVPairCorr
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.034
Dividend Share
2.97
Earnings Share
2.08
Revenue Per Share
2.7424
Quarterly Revenue Growth
0.18
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.